Innovation is the sole driver for Japanese pharma in the short-term, according to Global Biopharma Outlook 2011: Japanese Pharma, a report added to the offering of Research and Markets. This report identifies and names innovation driven, small cap companies. It finds that some of the large pharma R&D pipelines are rich and this extends to individual companies.
The thesis for pure generic companies has played out well for 2009-10 and this report does not see further drivers for this segment until 2012. New entrants like Daiichi-Sankyo-ESPHA will emerge as winners in the generic space.
Generics set to take 25% of volume by 2012
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze